JP5964752B2 - 癌の臨床転帰を予測する方法 - Google Patents

癌の臨床転帰を予測する方法 Download PDF

Info

Publication number
JP5964752B2
JP5964752B2 JP2012540103A JP2012540103A JP5964752B2 JP 5964752 B2 JP5964752 B2 JP 5964752B2 JP 2012540103 A JP2012540103 A JP 2012540103A JP 2012540103 A JP2012540103 A JP 2012540103A JP 5964752 B2 JP5964752 B2 JP 5964752B2
Authority
JP
Japan
Prior art keywords
il6st
normalized
level
rna
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012540103A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013514058A (ja
Inventor
ビー． ベイカー，ジョフリ
ビー． ベイカー，ジョフリ
ティー． クローニン，モーリーン
ティー． クローニン，モーリーン
コリン，フランソア
リュー，メイ−ラン
Original Assignee
ジェノミック ヘルス， インコーポレイテッド
ジェノミック ヘルス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェノミック ヘルス， インコーポレイテッド, ジェノミック ヘルス， インコーポレイテッド filed Critical ジェノミック ヘルス， インコーポレイテッド
Publication of JP2013514058A publication Critical patent/JP2013514058A/ja
Application granted granted Critical
Publication of JP5964752B2 publication Critical patent/JP5964752B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2012540103A 2009-11-23 2010-11-19 癌の臨床転帰を予測する方法 Active JP5964752B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26376309P 2009-11-23 2009-11-23
US61/263,763 2009-11-23
PCT/US2010/057490 WO2011063274A2 (en) 2009-11-23 2010-11-19 Methods to predict clinical outcome of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016129697A Division JP2016214245A (ja) 2009-11-23 2016-06-30 癌の臨床転帰を予測する方法

Publications (2)

Publication Number Publication Date
JP2013514058A JP2013514058A (ja) 2013-04-25
JP5964752B2 true JP5964752B2 (ja) 2016-08-03

Family

ID=44060376

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2012540103A Active JP5964752B2 (ja) 2009-11-23 2010-11-19 癌の臨床転帰を予測する方法
JP2016129697A Pending JP2016214245A (ja) 2009-11-23 2016-06-30 癌の臨床転帰を予測する方法
JP2018145578A Active JP7042717B2 (ja) 2009-11-23 2018-08-02 癌の臨床転帰を予測する方法
JP2020218527A Pending JP2021058207A (ja) 2009-11-23 2020-12-28 癌の臨床転帰を予測する方法
JP2022123265A Pending JP2022166064A (ja) 2009-11-23 2022-08-02 癌の臨床転帰を予測する方法
JP2022129605A Pending JP2022169647A (ja) 2009-11-23 2022-08-16 癌の臨床転帰を予測する方法
JP2023213416A Pending JP2024037948A (ja) 2009-11-23 2023-12-18 癌の臨床転帰を予測する方法

Family Applications After (6)

Application Number Title Priority Date Filing Date
JP2016129697A Pending JP2016214245A (ja) 2009-11-23 2016-06-30 癌の臨床転帰を予測する方法
JP2018145578A Active JP7042717B2 (ja) 2009-11-23 2018-08-02 癌の臨床転帰を予測する方法
JP2020218527A Pending JP2021058207A (ja) 2009-11-23 2020-12-28 癌の臨床転帰を予測する方法
JP2022123265A Pending JP2022166064A (ja) 2009-11-23 2022-08-02 癌の臨床転帰を予測する方法
JP2022129605A Pending JP2022169647A (ja) 2009-11-23 2022-08-16 癌の臨床転帰を予測する方法
JP2023213416A Pending JP2024037948A (ja) 2009-11-23 2023-12-18 癌の臨床転帰を予測する方法

Country Status (13)

Country Link
US (4) US20110123990A1 (show.php)
EP (4) EP3556867A1 (show.php)
JP (7) JP5964752B2 (show.php)
AU (1) AU2010321829B2 (show.php)
CA (2) CA2776751C (show.php)
DK (1) DK2504451T3 (show.php)
ES (1) ES2735993T3 (show.php)
HU (1) HUE044374T2 (show.php)
IL (5) IL219051A (show.php)
MX (3) MX363817B (show.php)
NZ (1) NZ599194A (show.php)
PL (1) PL2504451T3 (show.php)
WO (1) WO2011063274A2 (show.php)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
EP2163650B1 (en) 2004-04-09 2015-08-05 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
ES2778851T3 (es) * 2004-11-05 2020-08-12 Genomic Health Inc Predicción de la respuesta a la quimioterapia mediante el uso de marcadores de expresión génica
WO2007123772A2 (en) 2006-03-31 2007-11-01 Genomic Health, Inc. Genes involved in estrogen metabolism
RU2011102743A (ru) * 2008-06-26 2012-08-10 Дана-Фарбер Кэнсер Инститьют, Инк. (Us) Характерные признаки и детерминанты, связанные с метастазированием, и способы их применения
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
DK177532B1 (en) 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
HUE044374T2 (hu) * 2009-11-23 2019-10-28 Genomic Health Inc Módszerek rák klinikai kimenetelének elõrejelzésére
EP3178944B1 (en) 2010-01-11 2019-05-15 Genomic Health, Inc. Method to use gene expression to determine likelihood of clinical outcome of renal cancer
GB201009798D0 (en) 2010-06-11 2010-07-21 Immunovia Ab Method,array and use thereof
WO2012006447A2 (en) 2010-07-07 2012-01-12 Myriad Genetics, Inc. Gene signatures for cancer prognosis
IL243201A (en) 2010-07-27 2017-04-30 Genomic Health Inc A method for using gene expression to determine prostate cancer prognosis
US9605319B2 (en) 2010-08-30 2017-03-28 Myriad Genetics, Inc. Gene signatures for cancer diagnosis and prognosis
US8916344B2 (en) 2010-11-15 2014-12-23 Exact Sciences Corporation Methylation assay
US8361720B2 (en) 2010-11-15 2013-01-29 Exact Sciences Corporation Real time cleavage assay
EP2691547A4 (en) * 2011-03-26 2015-01-14 Univ Oregon Health & Science GENE EXPRESSION PREDICTORS FOR CANCER PROSPECTS
CA2840472A1 (en) * 2011-06-22 2012-12-27 Oncocyte Corporation Methods and compositions for the treatment and diagnosis of bladder cancer
US20140302042A1 (en) * 2011-07-01 2014-10-09 Dana-Farber Cancer Institute, Inc. Methods of predicting prognosis in cancer
US10559048B2 (en) * 2011-07-13 2020-02-11 The Multiple Myeloma Research Foundation, Inc. Methods for data collection and distribution
EP2744917A4 (en) * 2011-08-16 2015-10-14 Oncocyte Corp METHOD AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF BREAST CANCER
SG10202010758SA (en) * 2011-11-08 2020-11-27 Genomic Health Inc Method of predicting breast cancer prognosis
JP5805518B2 (ja) 2011-12-21 2015-11-04 株式会社島津製作所 マルチプレックス大腸がんマーカーパネル
NZ722902A (en) * 2012-01-31 2017-12-22 Genomic Health Inc Gene expression profile algorithm and test for determining prognosis of prostate cancer
GB201206323D0 (en) * 2012-04-10 2012-05-23 Immunovia Ab Methods and arrays for use in the same
EP2839034A4 (en) * 2012-04-20 2016-01-06 Sloan Kettering Inst Cancer ASSOCIATED GENE EXPRESSION PROFILES ASSOCIATED WITH METASTASISING BREAST CANCER
US20150299799A1 (en) 2012-10-05 2015-10-22 Michael Sturzl Method for Detecting an Increased Risk or Incidence of Colorectal Cancer
WO2014078700A1 (en) 2012-11-16 2014-05-22 Myriad Genetics, Inc. Gene signatures for cancer prognosis
KR101672531B1 (ko) * 2013-04-18 2016-11-17 주식회사 젠큐릭스 조기 유방암 예후 예측 진단용 유전자 마커 및 이의 용도
EP3825420A1 (en) * 2013-05-30 2021-05-26 Genomic Health, Inc. Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer
WO2014195032A1 (en) * 2013-06-07 2014-12-11 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy of fulvestrant in cancer patients
WO2015138769A1 (en) * 2014-03-12 2015-09-17 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for assessing patients with non-small cell lung cancer
EP3143160B1 (en) 2014-05-13 2019-11-06 Myriad Genetics, Inc. Gene signatures for cancer prognosis
FI3198035T3 (fi) 2014-09-26 2023-01-31 Menetelmiä lääkevasteen ennustamiseksi
US10184154B2 (en) 2014-09-26 2019-01-22 Mayo Foundation For Medical Education And Research Detecting cholangiocarcinoma
WO2016092299A1 (en) * 2014-12-09 2016-06-16 Medical Research Council Methods and kits for predicting the response to therapy of cancer
CN107532124B (zh) 2015-03-27 2022-08-09 精密科学公司 检测食管疾病
KR102811214B1 (ko) 2015-10-30 2025-05-27 이그잭트 사이언시즈 코포레이션 복합 증폭 검출 분석 및 혈장으로부터 dna의 분리 및 검출 방법
WO2017106790A1 (en) 2015-12-18 2017-06-22 Clear Gene, Inc. Methods, compositions, kits and devices for rapid analysis of biological markers
WO2018048354A1 (en) 2016-09-07 2018-03-15 Agency For Science, Technology And Research A method of identifying risk of cancer and therapeutic options
US9725769B1 (en) 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
AU2017258901A1 (en) 2016-12-30 2018-07-19 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients
WO2018140781A1 (en) 2017-01-27 2018-08-02 Exact Sciences Development Company, Llc Detection of colon neoplasia by analysis of methylated dna
WO2018212192A1 (ja) * 2017-05-18 2018-11-22 京都府公立大学法人 癌の予後及び／又は転移可能性を評価する方法及びマーカー
US12275994B2 (en) * 2017-06-22 2025-04-15 Clear Gene, Inc. Methods and compositions for the analysis of cancer biomarkers
AU2018327221A1 (en) 2017-11-13 2019-05-30 The Multiple Myeloma Research Foundation, Inc. Integrated, molecular, omics, immunotherapy, metabolic, epigenetic, and clinical database
US10648025B2 (en) 2017-12-13 2020-05-12 Exact Sciences Development Company, Llc Multiplex amplification detection assay II
US11549152B2 (en) * 2018-03-08 2023-01-10 University Of Notre Dame Du Lac Products for assessing colorectal cancer molecular subtype and risk of recurrence and for determining and administering treatment protocols based thereon
JP7199045B2 (ja) * 2018-04-13 2023-01-05 国立大学法人大阪大学 乳癌の予後に関する情報の取得方法、乳癌の予後の判定装置及びコンピュータプログラム
JP7444376B2 (ja) * 2018-09-21 2024-03-06 国立大学法人 東京大学 がんの予後判定方法
JP2019032334A (ja) * 2018-10-03 2019-02-28 イムノヴィア・アクチエボラーグ 乳癌関連の疾患状態を決定する方法およびこの方法における使用のためのアレイ
KR102216645B1 (ko) * 2018-10-29 2021-02-17 사회복지법인 삼성생명공익재단 폐암의 분자 아형 결정을 위한 바이오마커 패널 및 이의 용도
SG11202106130UA (en) * 2018-12-08 2021-07-29 Pfs Genomics Inc Transcriptomic profiling for prognosis of breast cancer
WO2020226333A1 (ko) * 2019-05-03 2020-11-12 주식회사 디시젠 암 예후 예측방법 및 이의 조성물
CN111235270B (zh) * 2019-08-29 2022-04-29 北京臻知医学科技有限责任公司 一种基于高通量测序法的肿瘤抗原表达检测引物及试剂盒
US12165747B2 (en) * 2020-01-23 2024-12-10 The Broad Institute, Inc. Molecular spatial mapping of metastatic tumor microenvironment
CA3210972A1 (en) * 2021-02-12 2022-08-18 Mammogen, Inc. Biomarkers for the diagnosis of breast cancer
WO2022192128A2 (en) * 2021-03-08 2022-09-15 Castle Biosciences, Inc. Determining prognosis and treatment based on clinical-pathologic factors and continuous multigene-expression profile scores
CN117116345B (zh) * 2023-07-24 2025-09-16 中国人民解放军军事科学院军事医学研究院 一种基于基因调控网络构建患者生存网络的方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7171311B2 (en) * 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
DK1410011T3 (da) * 2001-06-18 2011-07-18 Netherlands Cancer Inst Diagnose og prognose for brystcancerpatienter
AU2002322280A1 (en) * 2001-06-21 2003-01-21 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
EP2799555B1 (en) * 2002-03-13 2017-02-22 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
US20040067234A1 (en) * 2002-07-11 2004-04-08 Paz Einat Isocitrate dehydrogenase and uses thereof
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
EP3330875B1 (en) * 2003-07-10 2021-12-01 Genomic Health, Inc. Expression profile algorithm and test for prognosing breast cancer recurrence
WO2005086891A2 (en) * 2004-03-05 2005-09-22 Rosetta Inpharmatics Llc Classification of breast cancer patients using a combination of clinical criteria and informative genesets
WO2006037485A2 (en) * 2004-09-30 2006-04-13 Bayer Healthcare Ag Methods and kits for the prediction of therapeutic success and recurrence free survival in cancer therapy
WO2006103442A2 (en) * 2005-04-01 2006-10-05 Ncc Technology Ventures Pte. Ltd. Materials and methods relating to breast cancer classification
WO2006133460A2 (en) * 2005-06-09 2006-12-14 Yale University Methods for diagnosing and treating breast cancer based on a her/er ratio
US20070099209A1 (en) * 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
EP1907858A4 (en) * 2005-06-13 2009-04-08 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
TWI304443B (en) * 2005-12-30 2008-12-21 Nat Health Research Institutes Alpha-enolase specific antibody and method of use
WO2007123772A2 (en) * 2006-03-31 2007-11-01 Genomic Health, Inc. Genes involved in estrogen metabolism
WO2008155661A2 (en) * 2007-04-16 2008-12-24 Ipsogen Methods of assessing a propensity of clinical outcome for a female mammal suffering from breast cancer
WO2008150512A2 (en) * 2007-06-04 2008-12-11 University Of Louisville Research Foundation, Inc. Methods for identifying an increased likelihood of recurrence of breast cancer
WO2009095319A1 (en) * 2008-01-28 2009-08-06 Siemens Healthcare Diagnostics Gmbh Cancer prognosis by majority voting
WO2009132928A2 (en) * 2008-05-02 2009-11-05 Siemens Healthcare Diagnostics Gmbh Molecular markers for cancer prognosis
EP2607497B1 (en) * 2008-05-12 2014-10-01 Genomic Health, Inc. Tests to predict responsiveness of cancer patients to chemotherapy treatment options
HUE044374T2 (hu) * 2009-11-23 2019-10-28 Genomic Health Inc Módszerek rák klinikai kimenetelének elõrejelzésére

Also Published As

Publication number Publication date
IL249159A0 (en) 2017-01-31
NZ599194A (en) 2014-07-25
JP2022169647A (ja) 2022-11-09
MX391499B (es) 2025-03-21
AU2010321829A1 (en) 2012-05-03
IL264072B (en) 2020-08-31
IL219051A (en) 2016-12-29
US20210062275A1 (en) 2021-03-04
DK2504451T3 (da) 2019-08-05
MX2019003811A (es) 2019-08-05
HUE044374T2 (hu) 2019-10-28
IL257063B (en) 2019-01-31
US20170211154A1 (en) 2017-07-27
IL276487B (en) 2022-03-01
ES2735993T3 (es) 2019-12-23
JP2016214245A (ja) 2016-12-22
JP2013514058A (ja) 2013-04-25
EP4350001A2 (en) 2024-04-10
EP2504451A4 (en) 2016-07-06
CA2776751A1 (en) 2011-05-26
WO2011063274A3 (en) 2014-03-27
JP2022166064A (ja) 2022-11-01
EP2504451A2 (en) 2012-10-03
EP4350001A3 (en) 2024-06-19
MX363817B (es) 2019-04-04
IL276487A (en) 2020-09-30
IL219051A0 (en) 2012-06-28
EP3739060A1 (en) 2020-11-18
CA3043089A1 (en) 2011-05-26
JP7042717B2 (ja) 2022-03-28
CA2776751C (en) 2019-07-02
US20110123990A1 (en) 2011-05-26
US20190241967A1 (en) 2019-08-08
MX2012005822A (es) 2012-06-19
EP3556867A1 (en) 2019-10-23
JP2021058207A (ja) 2021-04-15
MX337650B (es) 2016-03-14
EP2504451B1 (en) 2019-06-05
JP2024037948A (ja) 2024-03-19
IL264072A (en) 2019-02-28
JP2018196385A (ja) 2018-12-13
AU2010321829B2 (en) 2015-07-30
PL2504451T3 (pl) 2019-09-30
WO2011063274A2 (en) 2011-05-26

Similar Documents

Publication Publication Date Title
JP7042717B2 (ja) 癌の臨床転帰を予測する方法
JP7042784B2 (ja) 遺伝子発現を用いた前立腺癌の予後を定量化する方法
JP6351112B2 (ja) 前立腺癌の予後を定量化するための遺伝子発現プロフィールアルゴリズムおよび試験
JP6147755B2 (ja) 乳癌の予後を予測する方法
JP7301798B2 (ja) 腎臓がんを有する患者に対する再発スコアを計算するための遺伝子発現プロファイルアルゴリズム
EP3178944A2 (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
JP7239477B2 (ja) 前立腺がんにおける後期臨床エンドポイントを評価するためのアルゴリズムおよび方法
WO2015066068A1 (en) Methods of incorporation of transcript chromosomal locus information for identification of biomarkers of disease recurrence risk
WO2014130617A1 (en) Method of predicting breast cancer prognosis
WO2014130444A1 (en) Method of predicting breast cancer prognosis
HK40014990A (en) Methods to predict clinical outcome of cancer
HK40052881A (en) Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer
AU2017216545A1 (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
NZ752676B2 (en) Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer
HK1223132B (en) Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer
NZ711680B2 (en) Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150123

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150422

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150508

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150821

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151119

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160219

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160603

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160630

R150 Certificate of patent or registration of utility model

Ref document number: 5964752

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250